The value of Cord Tissue over Bone Marrow
The Cord Tissue
Cord tissue, which refers to the connective tissue of the umbilical cord (not the cord blood inside of it) is an easily accessible source of stem cells when a baby is born. The type of umbilical cord stem cells that exist in great quantities in the tissue are called mesenchymal stem cells (MSCs). MSCs collected from umbilical cord tissue are genetically unique to your baby and family. Cord tissue is routinely discarded along with the placenta after birth. Parents-to-be who want to expand their baby’s options for future medical treatment should consider banking stem cells from their baby’s cord tissue. While MSCs are not currently being used for medical therapies, they are the subject of over 200 clinical trials. Research has indicated that MSCs hold the promise of being able to someday treat debilitating conditions such as heart disease, type 1 diabetes, lung cancer, Parkinson’s Disease, and injuries to bones and cartilage. Saving stem cells from cord tissue is one of the best first decisions you can make for your child’s future.
Mesenchymal stem cells from the umbilical cord tissue are more proliferative; hence larger numbers can be obtained on expansion from small initial numbers.
Laboratory techniques are now well developed, that allow obtaining unlimited numbers of purified mesenchymal precursor cells, and thereby make available these valuable stem cells therapeutic use more than once.
Approaching regulatory approval
Mesenchymal stem cells are now being used in over 100 clinical trials, including two phase III clinical trials. Ease in administration: Unlike other cell therapies these cells are administered through standard IV, like many of the other drugs that are given to patients.
These stem cells are well tolerated, with no patient deaths, no toxicity or any adverse side effects reported, thus providing for large-scale clinical use.
Usage of Mesenchymal Stem Cells
MSCs, are multipotent stem cells that can differentiate into a variety of cell types, including: osteoblasts (bone cells), chondrocytes (cartilage cells) and adipocytes (fat cells).
Mesenchymal stem cells are capable of self-renewal and differentiation into various connective tissue lineages.
Mesenchymal stem cells (MSCs) have been isolated from bone marrow, periosteum, trabecular bone, adipose tissue, synovium, skeletal muscle and deciduous teeth.
These cells have the capacity to differentiate into cells of connective tissue lineages, including bone, fat, cartilage and muscle.
MSCs can also express phenotypic characteristics of endothelial, neural, smooth muscle, skeletal myoblasts, and cardiac myocyte cells.
When induced into the infarcted heart, MSCs prevent deleterious remodeling and improve recovery.
Clinical use of cultured human MSCs (hMSCs) has begun for cancer patients, and recipients have received autologous or allogeneic MSCs.
MSCs can be used allogeneically, delivered systemically, and differentiate into a cardiomyocytelike. Phenotype when implanted in healthy myocardium.
MSCs can be readily transduced by a variety of vectors and maintain transgene expression after in vivo differentiation.
List of Diseases
List of diseases that can be potentially treated using Cord Tissue stem cells
Chronic Obstructive Pulmonary Disease
Critical Limb Ischemia
Graft vs Host Disease
Cryoviva Biotech Pvt. Ltd.
129, Pace City -1,Sector-37,
Gurugram, Haryana 122001 India
Tollfree No. : 1800 3002 2796
Helpline No. : (+91) 9582284444
Landline No. : 0124-3341301-305
© 2020 Cryoviva India. All rights reserved